Connect with us

Headlines

Smoking May Cause Loss of Color Vision, Study Suggests

The findings indicated significant changes in red-green and blue-yellow color vision.

mm

Published

on

Smoking more than 20 cigarettes a day can damage your vision, researchers have found.

The study included 71 healthy people who smoked fewer than 15 cigarettes in their lives and 63 who smoked more than 20 cigarettes a day, were diagnosed with tobacco addiction and reported no attempts to stop smoking. The participants were between the ages of 25 and 45 and had normal or corrected-to-normal vision as measured by standard visual acuity charts, according to a Rutgers press release.

Podcast: More Ways to Motivate Your Own Eyecare Business Team
INVISION Podcast

Podcast: More Ways to Motivate Your Own Eyecare Business Team

Podcast: Why Can’t We All Just Get Along?
INVISION Podcast

Podcast: Why Can’t We All Just Get Along?

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare
Try Not to Blink

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare

The researchers looked at how participants discriminated contrast levels (subtle differences in shading) and colors while seated 59 inches from a 19-inch cathode-ray tube monitor that displayed stimuli while researchers monitored both eyes simultaneously.

The findings indicated significant changes in the smokers’ red-green and blue-yellow color vision, which suggests that consuming substances with neurotoxic chemicals, such as those in cigarettes, may cause overall color vision loss. They also found that the heavy smokers had a reduced ability to discriminate contrasts and colors when compared to the non-smokers.

“Cigarette smoke consists of numerous compounds that are harmful to health, and it has been linked to a reduction in the thickness of layers in the brain, and to brain lesions, involving areas such as the frontal lobe, which plays a role in voluntary movement and control of thinking, and a decrease in activity in the area of the brain that processes vision,” said co-author Steven Silverstein, director of research at Rutgers University Behavioral Health Care.

“Previous studies have pointed to long-term smoking as doubling the risk for age-related macular degeneration and as a factor causing lens yellowing and inflammation. Our results indicate that excessive use of cigarettes, or chronic exposure to their compounds, affects visual discrimination, supporting the existence of overall deficits in visual processing with tobacco addiction.”

Advertisement

The research appears in the journal Psychiatry Research.

Although the research did not give a physiological explanation for the results, Silverstein said that since nicotine and smoking harm the vascular system, the study suggests they also damage blood vessels and neurons in the retina.

The Centers for Disease Control and Prevention estimates that 34.3 million adults in the U.S. currently smoke cigarettes and that more than 16 million live with a smoking-related disease, many of which affect the cardiovascular system.

Silverstein said the findings also suggest that research into visual processing impairments in other groups of people, such as those with schizophrenia who often smoke heavily, should take into account their smoking rate or independently examine smokers versus non-smokers.

The study was made available online in November 2018 ahead of final publication in print in January 2019

The study was conducted by researchers from the Perception, Neuroscience and Behavior Laboratory in Brazil with Silverstein as a consultant.

Advertisement

Advertisement

SPONSORED VIDEO

Promoted Headlines

Want more INVISION? Subscribe to our newsletter.

Comment

Headlines

Chain Retailer to Close All Stores, Evaluate Options for Optical Business

The company was unable to find a buyer.

mm

Published

on

GREEN BAY, WI — Retail chain Shopko announced that it will wind down its operations and that it is “evaluating strategic options” for its optical business.

The company said in a press release that despite its best efforts, it was “unable to find a buyer for its go-forward business as a going concern.”

“As a result, Shopko will commence an orderly wind-down of its retail operations beginning this week,” the company stated.

USA Today reports that Shopko announced in February its intent to close 250 stores, which would amount to 70 percent of its locations. That plan came as the company “attempted to scale back the business and work through bankruptcy to restore profitability and attract a buyer or investor,” according to the newspaper.

Now, the company instead plans to close all stores by mid-June, USA Today reports.

The company will not move forward with the auction that it previously contemplated, and Gordon Bros. will oversee a liquidation process that is expected to conclude 10 to 12 weeks from now, according to the release.

“This is not the outcome that we had hoped for when we started our restructuring efforts,” said Russ Steinhorst, CEO. “We want to thank all of our teammates for their hard work and dedication during their time at Shopko.”

As for the optical business, Shopko had originally hoped to spin off the business into standalone locations, USA Today reports.

Now the optical business will be among the assets that Shopko seeks to liquidate, according to the newspaper.

WLUK-TV reports: “As of now, four Shopko optical locations will remain open until further evaluation: Mequon, Oshkosh, Waukesha and Omaha, Nebraska.”

In its Jan. 16 bankruptcy filing, Shopko reported having less than $1 billion in assets and between $1 billion and $10 billion in liabilities.

Continue Reading

Headlines

Alcon Makes $285M Acquisition

It bought PowerVision Inc., a medical device development company.

mm

Published

on

FORT WORTH, TX – Alcon announced that it has acquired PowerVision Inc., a privately held, U.S.-based medical device development company focused on creating fluid-based intraocular lens implants.

Alcon paid $285 million to PowerVision at closing, with additional payments to be made based on regulatory and commercial milestones starting in 2023, according to a press release from Alcon, a division of Novartis.

Podcast: More Ways to Motivate Your Own Eyecare Business Team
INVISION Podcast

Podcast: More Ways to Motivate Your Own Eyecare Business Team

Podcast: Why Can’t We All Just Get Along?
INVISION Podcast

Podcast: Why Can’t We All Just Get Along?

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare
Try Not to Blink

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare

The acquisition “furthers Alcon’s commitment to bring this innovative, accommodating lens to cataract patients throughout the world,” the release stated.

Financial terms of the deal were not disclosed.

Commercial availability of PowerVision’s IOL technology will be determined following significant additional development and clinical trials of the intraocular lens, according to the release.

“As the industry leader in cataract surgery, we’re eager to accelerate development of this potentially breakthrough accommodating lens technology,” said Michael Onuscheck, president of Global Business and Innovation. “By treating cataracts and restoring natural, continuous range of vision, this intraocular lens may be the preferred IOL for cataract surgery patients who desire spectacle independence.”

PowerVision’s lens design utilizes the eye’s natural accommodating response to transport fluid in the intraocular lens which is implanted in the eye’s capsular bag.

While most presbyopia-correcting intraocular lenses use a multifocal design that distributes light between different focal points, PowerVision’s fluid-based design creates a continuously variable monofocal lens, utilizing the natural contraction of the eye’s muscles, according to the release. This technology allows the patient to actively focus on objects, just as the natural crystalline lens does in a youthful eye, providing patients with a natural, continuous range of vision.

“We’re thrilled to officially join Alcon and its pioneering history of launching new innovation in the field of ophthalmology,” said Barry Cheskin, president and CEO and co-founder of PowerVision. “We look forward to bringing this innovative IOL technology to eye care providers and customers in the years ahead.”

Continue Reading

Headlines

Marchon Eyewear Co-Founder Dies

Alfred Berg was 67.

mm

Published

on

Alfred Berg, who co-founded Marchon Eyewear in 1983, has died, WWD reports.

He was 67.

In the beginning, Berg served as CEO and president of Marchon. In 2008, Berg and partners sold Marchon to VSP Global.

Berg “left an incredible legacy behind, having built one of the world’s greatest and largest eyewear companies, which still thrives today thanks to his vision and competitive spirit,” said Rob Lynch, board member of VSP Global, according to WWD. Lynch was leading the company when it bought Marchon.

Advertisement

Nicola Zotta, current CEO of Marchon, was quoted saying, “Al will be greatly missed by all who knew him and we will honor his legacy by continuing to make Marchon the most admired global eyewear company in the world.”

Among Marchon’s licenses today are Calvin Klein and Chloé.

Read more at the WWD

Continue Reading

Advertisement

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Instagram

Most Popular